The city of Sarasota, Florida, currently has 5 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
NCT06538116
Recruiting
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/22/2025
Locations: Intercoastal Medical Group - Hyde Park, Sarasota, Florida
Conditions: Alzheimer Disease
Register for Updates
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357
Recruiting
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
07/11/2025
Locations: Intercoastal Medical Group, Inc., Sarasota, Florida
Conditions: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Register for Updates
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688
Recruiting
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/20/2025
Locations: The Roskamp Institute, Sarasota, Florida
Conditions: Alzheimer Disease
Register for Updates
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833
Recruiting
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Sarasota, Florida
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
Preventing Alzheimer's With Cognitive Training
NCT03848312
Recruiting
Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and is indicative of higher risk for dementia. In addition to the obvious health and quality-of-life ramifications of dementia, there are high direct (e.g., subsidizing residentia... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/24/2024
Locations: The Roskamp Institute, Sarasota, Florida
Conditions: Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias
Register for Updates